New Delhi: Coronavirus Vaccine-induced Antibody Titre (COVAT) in the study found that seropositivity rates and the median anti-spike antibody titer were significantly higher in Astra Zeneca’s Covishield as compared to Bharat Biotech’s Covaxin.
The research was done on 515 health care workers of India, who have received both doses of either of the two COVID vaccines and out of which 95.0 percent showed seropositivity after two doses of both vaccines.
“Amongst the 325 Male, 227 Female Health Care Workers (552 workers), 456 and 96 received the first dose of Covishield and Covaxin respectively. Overall, 79.3 percent showed seropositivity after the first dose.”
Responder rate and median (IQR) rise in anti-spike antibody were significantly higher in Covishield vs. Covaxin recipient (86.8 vs. 43.8 percent; 61.5 vs. 6 AU/ml; both p<0.001),” the study said.
The study further said that SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four-time points between 21 days or more after the first dose to 6 months after the second dose.
Bharat Biotech’s Covaxin and Oxford-Astra Zeneca’s Covishield are manufacturing by Serum Institute of India and received the approval of emergency use authorization by DCGI-CDSCO in January 2021.
…………..
